Physician profile
Christine Won
NPI 1750350252
$1,497.37
in general payments reported to CMS, 2019-2025
18 companies · $431 in 2025
The $431 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $24.00 · 2021: $178 · 2022: $326 · 2023: $67.93 · 2024: $315 · 2025: $431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $814.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $813.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $323.55 | 2019-2025 | Ozempic, Rybelsus |
| Biohaven Pharmaceutical Holding Company LTD. | $226.48 | 2022 | |
| Abbvie INC. | $186.02 | 2021-2024 | Ubrelvy |
| Amgen INC. | $184.35 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $126.32 | 2025 | Reblozyl |
| Lilly USA, LLC | $123.01 | 2021-2025 | Zepbound, Mounjaro |
| Biohaven Pharmaceuticals, INC. | $42.25 | 2021 | |
| Jazz Pharmaceuticals INC. | $41.39 | 2019 | |
| Exact Sciences Corporation | $31.03 | 2025 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $30.16 | 2023-2025 | Contrave |
| Kowa Pharmaceuticals America, INC. | $25.23 | 2019 | |
| Pfizer INC. | $24.93 | 2024 | |
| Astellas Pharma US INC | $24.87 | 2019 | |
| Esperion Therapeutics, INC. | $24.79 | 2024 | Nexletol |
| Merck Sharp & Dohme LLC | $23.13 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $22.02 | 2025 | Breztri |
| Melinta Therapeutics, LLC | $19.28 | 2021 | |
| Glaxosmithkline, LLC. | $18.56 | 2023 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Won listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.